Global Cystic Fibrosis Therapeutics Set to Improve Lives of Thousands in the coming decade:


  • According to ReportLinker Global Cystic Fibrosis Therapeutics market set to grow at 10.8% in the period 2020-2028
  • Factors such as increased cases, increased investment in the field are boosting growth

Cystic fibrosis is a disease that causes mucus to gather, mainly in lungs and kidneys which may hamper normal functioning of those organs and even cause failure of those organs. Other organs affected may include pancreas and liver. Cystic fibrosis is a hereditary disease and is usually detected during early childhood.

Though the disease in fatal and incurable, scientists believe that with the help of advanced therapeutics combined with proper nutrition, a patient’s life span can be considerably increased. However, the introduction of new generic drugs and high cost of treatments involved impede Cystic Fibrosis Therapeutics market development.

Cystic fibrosis is caused by a mutation of cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is mainly responsible for the normal body functions like sweating, mucus production and other bodily secretions. Patients may experience difficulty in breathing, mucus formation, fatty stool etc.

The global cystic fibrosis therapeutics market is expected to grow at a record pace in the coming decade as personalized drug therapy & molecular prosthetics as a form of treatment become readily available. The market is expected to reach $9,277.3 million by 2026. Research and Development investments made in the healthcare field by various government agencies is also driving market growth forward.

The Global Cystic Fibrosis Therapeutics market is mainly segmented on the basis of region, top selling drugs, mode of administration etc. Throughout the world nearly 70,000 people are known to be affected by cystic fibrosis and 75% of them are usually diagnosed before the age of 2.